A5067203388- Multiple Myeloma Research and Treatments
- Cancer Treatment and Pharmacology
- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Amoebic Infections and Treatments
- Lung Cancer Research Studies
- Cancer Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Glioma Diagnosis and Treatment
- Cancer Research and Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- COVID-19 Clinical Research Studies
- Gallbladder and Bile Duct Disorders
- Neuroendocrine Tumor Research Advances
- Neuroblastoma Research and Treatments
- Cancer and Skin Lesions
- Cancer Cells and Metastasis
- Otolaryngology and Infectious Diseases
- Viral-associated cancers and disorders
- Human-Animal Interaction Studies
- Colorectal Cancer Treatments and Studies
- Veterinary Practice and Education Studies
- COVID-19 diagnosis using AI
- Head and Neck Surgical Oncology
Medical College of Wisconsin
2023-2025
Froedtert Hospital
2024-2025
Rochester General Hospital
2020-2022
Taylor's University
2018-2022
Unity Health System
2022
Immunocompromised individuals with hematological malignancy have increased risk for poor outcomes and death from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This special population may mount a suboptimal response to vaccination. We assessed the effectiveness of tixagevimab cilgavimab (Evusheld), monoclonal antibody combination against SARS-CoV-2, in conjunction standard preventative measures, at preventing symptomatic incident infection.Patients aged 18 years older...
Abstract Background We aimed to investigate the prognostic role of examined (dissected) lymph nodes (ELNs), negative LNs (NLNs), and positive (metastatic) (PLNs) counts LN ratio (LNR = PLNs/ELNs×100) in patients with major salivary gland cancer (SGC). Methods Data were retrieved for SGC diagnosed between 1988 2011 from Surveillance, Epidemiology, End Results program. have included 5446 SGC. Most had parotid (84.61%). Patients having >18 ELNs, >4 PLNs, >33.33% LNR associated a worse...
725 Background: Pancreatic ductal adenocarcinoma (PDAC) is largely driven by oncogenic alterations in the KRAS , TP53 CDKN2A/B and SMAD4 genes. G12R accounts for nearly 20% of PDAC, biologically unique, offers potential improved response to MEK inhibitor (MEK-inh)-based therapy. As part MCW-Master-PREDICT (NCT05802069) observational study, we evaluated efficacy MEK-inh-based therapy matched unique molecular tumor each patient as recommended board. Methods: From March 2022 December 2023, 8...
710 Background: Recent advances in therapeutic vaccines show promise for KRAS -mutated pancreatic cancer (PC), with ongoing clinical trials exploring their potential further. Lymphocytes are essential generating vaccine-induced immune response. Patients who develop lymphopenia following neoadjuvant radiation therapy (RT) frequently excluded from these vaccine trials. We aimed to assess how different modalities of RT impact the severity and incidence lymphopenia. Methods: identified patients...
726 Background: Up to 95% of pancreatic ductal adenocarcinomas (PDAC) are driven by oncogenic alterations in the KRAS gene, with G12D (40%) and G12V (30%) mutations being most common. However, cases, accompanied other tumor suppressors such as TP53 , CDKN2A/B SMAD4 . Therefore, targeting alone may not be sufficient for effective treatment PDAC As part MCW-Master-PREDICT (NCT05802069) observational study, we evaluated effectiveness MEK inhibitor (MEK-inh)-based therapy, tailored unique...
Patients with neuroendocrine tumors (NETs) are at increased risk of mortality from competing causes in light the improvement overall survival over recent decades. The purpose this study was to explore deaths and factors associated mortality.The Surveillance, Epidemiology, End Results database used identify patients diagnosed NETs between 1973 2015. Risk estimated by standardized ratios (SMRs) using Fine Gray multivariate regression model.Of 29,981 NET patients, 42.5% that occurred during...
Primary pulmonary lymphomas (PPLs) are rare lymphoproliferative malignancies arising from the lungs. The prognostic factors and optimal management of PPL have not been clearly defined due to its rarity. This study sought characterize significant develop a validated nomogram for individualized prediction survival outcomes in patients with PPL. A total 2325 diagnosed between 1983 2010 were identified using Surveillance, Epidemiology, End Results (SEER) database. Older age at diagnosis, males,...
Objectives: Primary gallbladder cancer (GBC) is the most common biliary tract with poor survival despite aggressive treatment. This study aimed to investigate trends of GBC incidence and incidence-based mortality (IBM) over last 4 decades. Materials Methods: cases diagnosed between 1973 2015 were retrieved from Surveillance, Epidemiology, End Results (SEER) database. Incidence rates, IBM annual percent changes (APCs) calculated stratified according population tumor characteristics. Results:...
Orthostatic hypotension (OH) is a well-recognized phenomenon occurring in multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT), and associated with significant morbidity mortality. A retrospective analysis of admitted for first ASCT between June 2012 April 2014 found that 161/222 (73%) were diagnosed OH during the course ASCT, including 51 who to have on day orthostatic vitals check. Excluding these patients, 110/171 (64%) developed peri-transplant period, at...
A patient with history of myelodysplastic syndrome (MDS) presented multifocal pneumonia and was found to have Philadelphia chromosomepositive (Ph+) acute myeloid leukemia (AML). tyrosine kinase inhibitor (TKI) added decitabine venetoclax combination, providing a molecular cytogenetic complete response despite additional abnormalities. She remains in remission after eleven cycles treatment. Our report describes the tolerability success triplet regimen that incorporates TKI backbone high-risk...
Prior studies report a greater incidence of second primary malignancy (SPM) among patients with myeloproliferative neoplasms, although the true risk in myelofibrosis (PMF) has not been elucidated. We utilized Surveillance, Epidemiology, and End Results database to evaluate SPM PMF analyzed effects sociodemographic factors on SPM. Out 5273 patients, 385 (7.30%) developed occurred at SIR 1.95 (95% CI 1.76-2.15) AER 149.01 per 10,000 population. A significantly higher melanoma (SIR 1.76, 95%...
Background: Patients with malignancies including malignant gliomas have a relatively high risk for venous thromboembolism (VTE). Recent evidence has linked isocitrate dehydrogenase (IDH) mutation reduced VTE in glioma patients. This meta-analysis aims to quantify the association of IDH status risks patients.Methods: We searched PubMed, Google Scholar, Medline OVID, Cochrane library, Cumulative Index Nursing and Allied Health Literature databases identify relevant studies. The overall odd...